Currently, gene therapy for sickle cell disease is only available as part of clinical trials. That means that the full risks and benefits of the treatment have not been assessed in a large number ...

Now 33, Stephenson was one of the first to receive sickle cell gene therapy in a clinical trial six years ago. Before the treatment, Stephenson lived her life on a razor's edge.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

In early December, the Food and Drug Administration approved a gene-editing treatment for sickle cell disease, the first for any illness. One patient helped pave the way.

Gene editing could be a game changer for patients with sickle cell disease 05:36. The U.S. Food and Drug Administration on Friday approved a landmark gene-editing treatment for sickle cell disease ...

By Dec. 20, the FDA will determine the fate of a second gene therapy for people with sickle cell, lovo-cel by Bluebird Bio, which relies on a more established approach to gene therapy.

New gene therapy improves the life of 18-year-old with Sickle Cell Disease which affects 5,000 New Jersey residents living with the condition. Skip to Article Set weather ...

He first had sickle cell symptoms at age 2, and his symptoms were only getting worse as he got older. In this method, the researchers removed blood stem cells from Branden, which were then exposed to ...

In recent years, clinical trials of three gene therapies for sickle cell have produced astonishing results for a few dozen lucky participants like Helen, raising hopes that a cure could be at hand ...

A Mississippi woman's life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared.

She knows new gene therapies may provide long-term relief to some of the 100,000 Americans like her who suffer from sickle cell disease. But she's holding off trying one. Sign up here.

Gerald Quartey, 18, recently became the first patient to receive Lyfgenia, a one-time, cell-based gene therapy for Sickle Cell Disease for adults and adolescents 12 and older.